International Conference on

Vaccines & Vaccination

Osaka, Japan   July 23-25, 2018

Vaccine 2018

Osaka, Japan July 23-25, 2018

Theme: Understanding the Importance of Vaccines in the Present Era

Meetings International takes the pride in announcing its premier International Conference on Vaccines & Vaccination scheduled in Osaka, Japan during July 23-25, 2018. A leading forum for Microbiologist, researchers, scientists, elite professors, Technologist and students provides the ideal environment to disseminate and gain current knowledge in this field.The main theme of the conference is ''Understanding the Importance of Vaccines in the Present Era''

Meetings International provides a global platform for Medical, Biotech, Pharmaceutical and Healthcare Professionals to Exchange Ideas, Knowledge and Networking at 100+ International Conferences. It supports broad scope research and peer review at a broad range of specialists around the world. The key strategic objective of Meetings International is to communicate science and medical research between academia and industry.

Vaccine 2018 brings upon an incipient platform to share and discuss all the innovations and potential benefits and limitations of vaccines in preventing and control of diseases , The gathering incorporates Plenary lectures, keynote talks courses by eminent personalities from around the world  in addition to poster presentation, young researcher sessions, symposiums, workshop and Exhibitions. It focuses on a wide array of topics that include the following: Vaccination, Human vaccines - Infectious diseases & Non Infectious Diseases, Cancer and Immunotherapy Vaccine, Veterinary Vaccines, Clinical Research & Clinical Trails, Novel Vaccines - Research and Development, Pregnancy & Neonatal Vaccines, Vaccination for Bacterial and Viral Diseases, Vaccines & Immunizations, Antibodies Research, Vaccine safety & Efficacy, Vaccination for Emerging and Re-emerging diseases, Hepatitis Vaccines, HIV/AIDS Vaccines.

Vaccine 2018 conference leads confident that it will definitely offer all participants an unforgettable experience in exploring new opportunities. Hoping everyone to join us for this event in Osaka.Osaka is a designated city in the Kansai region of Japan. It was evaluated in Research & Development only. Osaka currently markets vaccines in Japan only and is growing its vaccine pipeline, including R&D projects for dengue and chikungunya. Osaka performs above average in Research & Development, and has clear access provisions for its late-stage vaccine candidate. While it does not currently market vaccines in countries in scope, it is taking steps to support affordability and supply of vaccines in its pipeline.

Track 1: New Vaccines

Vaccines are biological preparations made from the weakened or killed forms of microbes. They create immunity against a disease. A Traditional vaccine consists of agents that resemble the disease- causing organism. When these agents enter the human body they stimulate the immune system to recognize these agents as foreign and destroy them. The administration of vaccines is called vaccination.

Track 2: Infectious diseases & Non Infectious Diseases

The first vaccines for humans against viruses used weakened viruses to generate immunity without causing severe illness (e.g. the early smallpox vaccine that was derived from cowpox). The rabies vaccine was the first human vaccine where the virus was attenuated in a laboratory. vaccines against chronic infectious diseases aim at eliciting broad humoral and cellular immune responses against multiple target antigens.. It covers infectious disease targets and non-infectious disease targets.

Track  3: Cancer Vaccine

Cancer treatment vaccines are different from the vaccines that work against viruses. These vaccines endeavor to get the immune system to mount an assailment against cancer cells in the body. In lieu of averting disease, they are betokened to get the immune system to assail a disease that already subsists. Cancer vaccines work the same way, but they make the person’s immune system attack cancer cells. The goal is to avail treat cancer or to avail keep it from coming back after other treatments. But there are additionally some vaccines that may authentically avail avert certain cancers. These vaccines are made from genuine cancer cells that have been abstracted from the patient during surgery. The cells are altered (and killed) in the lab to make them more liable to be assailed by the immune system and then injected back into the patient. The patient’s immune system then assails these cells and any homogeneous cells still in the body.

Track 4: Veterinary Vaccines

Veterinary vaccines are to improve the health and welfare of animals and also  protect its health along public health, reducing animal suffering, enabling efficient production of food animals to feed the burgeoning human population, and greatly reducing the need for antibiotics to treat food and companion animals. Prominent examples include rabies vaccines and rinderpest vaccines. Recently for rabies a third generation rabies vaccine has been developed using recombinant technology for domestic animals and wildlife. Depending upon the expression system these vaccines are used either parenterally or orally. Oral rabies vaccines are widely used in foxes in Europe and in racoons in the USA.

Track 5: Trails in Vaccinology

A vaccine trial is a clinical trial that aims at establishing the safety and efficacy of a vaccine prior to it being licensed. A vaccine trial might involve forming two groups from the target population. Vaccine trials may take months or years to complete, since a sufficient time period must elapse for the subjects to react to the vaccine and develop the required antibodies.

Track 6: Novel Vaccines 

Vaccines have led to the global eradication of smallpox, the near global eradication of polio, and phenomenal reductions in measles infections in most of the developed world, The revelation of vaccinations has provoked to the nearby demolition of a couple of basic diseases and has enormously influenced prosperity for a decently insignificant exertion.

Track 7: Pregnancy & Neonantal Vaccines

Vaccines are given specifically depending on factors such as age, lifestyle, medical conditions , such as asthma or diabetes, type and locations of travel, and previous vaccinations. Benefits of vaccinating pregnant women usually outweigh potential risks when the likelihood of disease exposure is high, when infection would pose a risk to the mother or foetus, and when the vaccine is unlikely to cause harm. There is a unique CDC rules for the immunizations which are require after pregnancy.

Track 8: Vaccine-Preventable Diseases

Viral and bacterial vaccines decrease the percentile of severity of  illness in the living being and reduce the transmission of the pathogens to other susceptible living being. Viral vaccines contain inactivated viruses (alive but not capable of causing disease) thus they lost their ability to replicate and in order for it to bring about a response it contains more antigen than live vaccines. Attenuated or live vaccines contain the live form of the virus. These viruses are not pathogenic but are able to induce an immune response. Through these mechanisms, vaccines against smallpox, polio, measles and hepatitis B have had an enormous impact on world health over the last 50 years.

Track 9: Therapeutic Vaccination and Immunization

The vaccination helps the immune system to recognize and fight specific germs. Perfect immunity against a disease is not guaranteed through vaccination. Immunization refers to making someone immune against infections or diseases. Immunization is not only caused by Vaccines but there are also some diseases that cause immunization after an individual encounters and recovers from that disease.

Track 10: Passive vaccines

For many laboratory techniques Antibodies are vital. Even the molecules which cannot be seen by naked eyes are visible now due to their specificity and thus enable conclusions to be drawn about the target molecule and pathway of interest. Immunizer Genetic Engineering and Therapeutics meeting united a wide scope of members who were refreshed on the most recent advances in counter acting agent innovative work.

 Track 11: Vaccine Regulation and its Safety & Efficacy

Vaccines are some of the safest medical products available, but like any other medical product, there may be health risk. Accurate information about the value of vaccines as well as their possible        side-effects helps people to make informed decisions about vaccination.  Vaccine efficacy is the ability of vaccines to bring about the intended beneficial effects on vaccinated individuals in a defined population under ideal conditions of use. The potential benefits of an  effective vaccine.

Track 12: Emerging and Re-emerging diseases

Emerging infectious diseases present many hindrances with regard to vaccine development. The major obstacles to development of vaccines against emerging infectious diseases have generally not been regulatory in nature. In many cases, the scope of the threat from an emerging infectious disease is unknown at the time when vaccine development would optimally occur.

Track 13: Hepatitis Vaccines

Hepatitis is an inflammation of the liver. The condition can be self-limiting or can progress to fibrosis (scarring), cirrhosis or liver cancer. Hepatitis viruses are the most common cause of hepatitis in the world but other infections, toxic substances (e.g. alcohol, certain drugs), and autoimmune diseases can also cause hepatitis. Hepatitis Vaccines are many depending on its Category.

Track 14: HIV/AIDS Vaccines

Development of a HIV/AIDS immunization has been ease back on the grounds that established ways to deal with antibody improvement have not yielded an antibody. An AIDS vaccine does not yet exist, but efforts to develop a vaccine against HIV, the virus that causes AIDS, have been underway for many years. An HIV vaccine could be effective in either of two ways. A preventive vaccine would stop HIV infection occurring altogether, whereas a therapeutic vaccine would not stop infection, but would prevent or delay illness in people who do become infected, and might also reduce the risk of them transmitting the virus to other people. Although a preventive vaccine would be ideal, therapeutic vaccines would also be highly beneficial. The basic idea behind all HIV vaccines is to encourage the human immune system to fight HIV.

Why Japan?

Osaka was evaluated in Research & Development only. Osaka currently markets vaccines in Japan only and is growing its vaccine pipeline, including R&D projects for dengue and chikungunya. Osaka performs above average in Research & Development, and has clear access provisions for its late-stage vaccine candidate. While it does not currently market vaccines in countries in scope, it is taking steps to support affordability and supply of vaccines in its pipeline. For example, from 2016, Osaka has been developing a low-cost IPV with support from the Bill & Melinda Gates Foundation. The beginning stages of early traditions of visits to lovely destinations. Japan's rich history can be experienced most wherever in the country. With numerous old royal residences so far remaining the nation over, it's definitely not hard to set aside a trip back in chance to a place that is known for medieval rulers. The Travel and Tourism Competitiveness Report 2017 positions Japan fourth out of 141 countries for the most part, which was the best in Asia. Japan got for the most part high scores in all viewpoints, especially human services and cleanliness, wellbeing and security, social resources and business travel.

Vaccine & Vaccination  Market Research

Importance and scope

A vaccine is a biological preparation that provides active acquired immunity to a particular disease. The administration of vaccines is called vaccination. A vaccine typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, it then stimulates body's immune system to recognize the agent as a threat and destroy it.

Vaccination is one of the most successful achievements in medicine. Vaccine Immunology upgrades our comprehension of the resistant reaction in wellbeing and illness by exhibiting critical clinically applicable research, including new creature models for human immunologic infections. Vaccination itself cannot cause formation of disease against which it is intended. Vaccines have historically been the most effective means to fight and eradicate infectious diseases. Vaccinations of animals are used both to prevent their contracting diseases and to prevent transmission of disease to humans. Vaccination given during childhood is generally safe. Effectiveness of vaccination is unambiguously proven by regression up-to clearance of many diseases preventable by vaccination. Limitations to their effectiveness, nevertheless, exist. Influence of vaccination can be best illustrated on eradication of smallpox in the world one of the most contagious and deadly diseases in humans.

Global Vaccine Market

 The vaccines market is expected to reach USD 49.27 Billion by 2022 from USD 34.30 Billion in 2017, at a CAGR of 7.5%. The growth of the market is attributed to the rising prevalence of diseases, increasing government and nongovernment funding for vaccine development, and increasing investments by companies.

Newer and more expensive vaccines are coming into the market faster than ever before. Vaccine development: increasing investment. Tripled in value from USD 5B in 2000 to almost USD 24 B in 2013 – Influenza vaccine market: estimated at $2.9 billion in 2011 to $3.8 billion by 2018 – US : $1.6 billion in 2011 to $2.2 billion in 2018. Global market projected to rise to USD 100 B by 2025 .More than 120 new products in the development pipeline. Changing status of the vaccines within the pharmaceutical industry . New business model for vaccines is emerging.

Global Statistics of Vaccines

Global Influenza Vaccine Market – Will Increase to US$ 5.74 Billion by the Year 2022 – Research and Markets.

The study based on Evaluate Pharma survey shows that at the end of 2013 the sales volume of global vaccine market was $ 25.6 billion and is expected to rise to $41.3 billion by 2020.

Global antibacterial vaccination market

Global Antibacterial Drugs Market to 2022: Antibacterial Drug Market will Hit $35.6 Billion by 2022, as Efforts Increase to Tackle Antimicrobial Resistance - Research and Markets.

Global antibacterial vaccination market is expected to experience healthy growth across the forecast period due to rising profits for several classes of drugs. Vaccines will still be the leading revenue-generating drugs in the market in 2022, despite the influx of new protein synthesis inhibitors and the release of several new cell-wall synthesis inhibitors.

Conjugate vaccines to dominate the market in 2017-2018

Predicated on technology, the vaccines market is segmented into conjugate vaccines, inactivated and subunit vaccines, live attenuated vaccines, recombinant vaccines, and toxoid vaccines. In 2018, the conjugate segment is expected to account for the most immensely colossal quota of the vaccines market. The magnification in this market is mainly driven by incrementing investments by the regime of developing countries and elevating prevalence of infectious diseases.

Predicated on disease denotement, the pneumococcal segment is projected to grow at the highest CAGR during the forecast period.

By disease designation, the vaccines market is segmented into pneumococcal disease, influenza, DTP, hepatitis, human papillomavirus (HPV), rotavirus, meningococcal disease, MMR (measles, mumps, and rubella), varicella, polio, dengue, and other disease designations. The pneumococcal segment is expected to register the highest rate during the forecast period. The magnification in this segment can primarily be attributed to the incrementing regime investments in pneumococcal vaccination programs and high prevalence of pneumococcal disease.

Market outlook of the global human vaccine market

Technavio’s market research analyst presages the ecumenical human vaccine market to grow rapidly at a CAGR of more than 11% by 2020. This market’s steady magnification rate is heavily influenced by the inclusion of several pediatric vaccines in the national immunization schedule of sundry countries. This avails in incrementing the consumption of vaccines, which in turn fosters market magnification during the prognosticated period.

Associations & Societies Associated with Vaccines in and around Osaka:

  • Japanese Society for Immunology(JSI)
  • The Japanese Society for Vaccinology
  • The Japanese Society of Virology
  • The Japanese Association Of Medical Sciences
  • Japan Society of Immunology and Reproduction
  • Japan Pediatric Society

Global Associations & Societies Associated with Vaccines:

  • European Federation of Immunological Societies
  • The International Society for Interferon and Cytokine Research
  • The International Society of Neuroimmunology
  • British Society for Immunology
  • Infectious Diseases Society of America
  • The Society for Mucosal Immunology
  • The Society for Leukocyte Biology
  • Immune Deficiency Foundation
  • The International Union of Immunological Societies
  • European Society of Gene Therapy
  • Federation of African Immunological Societies
  • Federation of Clinical Immunology Societies

Universities associated with Vaccines globally:

  • Osaka University, Japan
  • Angeles University Foundation, Philippines
  • Moscow State Medical University, Russia
  • Shanghai Medical University, China
  • Qingdao University, China
  • University of Jordan, Jordan
  • Kasr El-Aini Faculty of Medicine, Cairo University, Egypt
  • Arak University of Medical Sciences, Iran
  • Oman Medical College, Oman
  • Riyadh.College of medicine, Saudi Arabia
  • University of Minho, Portugal
  • Medical University of Lublin, Poland
  • Saba University School of Medicine, Netherlands
  • University of Western Brittany, France
  • University of Southern Denmark, Denmark
  • Harvard University, USA
  • University of California--San Francisco, USA
  • Stanford University, USA
  • Yale University, USA
  • Johns Hopkins University, USA

Industries associated with Vaccines in worldwide:

  • GlaxoSmithKline plc (U.K.)
  • Pfizer, Inc. (U.S.)
  • Merck & Co., Inc. (U.S.)
  • Sanofi Pasteur SA (France)
  • CSL Limited (Australia)
  • Emergent BioSolutions, Inc. (U.S.)
  • Johnson & Johnson (U.S.)
  • MedImmune, LLC (U.S.)
  • Daiichi Sankyo Company, Limited (Japan).
  • Mitsubishi Tanabe Pharma Corporation (Japan)
  • Astellas Pharma Inc. (Japan)
  • Serum Institute of India (India)
  • Bavarian Nordic (Denmark)

Conclusion

Vaccines are necessary — and good hygiene, sanitation, clean water, and nutrition are insufficient for stopping infectious diseases. If we don’t maintain optimum rates of immunization or “herd immunity”, the diseases prevented by vaccination will return. While better hygiene, sanitation and clean water help protect people from infectious diseases, many infections can spread regardless of how clean we are. If people are not vaccinated, diseases that have become uncommon such as pertussis (whooping cough), polio and measles, will quickly reappear.

References

https://www.marketsandmarkets.com/PressReleases/vaccine-technologies.asp

http://www.who.int/immunization/programmes_systems/procurement/market/en/

https://www.technavio.com/report/global-vaccines-human-market

https://www.aboutpharma.com/blog/2017/05/02/global-influenza-vaccine-market-will-increase-to-us-5-74-billion-by-the-year-2022-research-and-markets/

  • New Vaccines
  • Infectious diseases & Non Infectious Diseases
  • Cancer Vaccines
  • Veterinary Vaccines
  • Trials in Vaccinology
  • Novel Vaccines
  • Pregnancy & Neonantal Vaccines
  • Vaccine-Preventable Diseases
  • Therapeutic Vaccination and Immunizations
  • Passive vaccines-therapeutic antibodies against infectious diseases
  • Vaccine Regulation and its Safety & Efficacy
  • Emerging and Re-emerging diseases
  • Hepatitis Vaccines
  • HIV/AIDS Vaccines